Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to 0.21.

  • Evoke Pharma's Equity Ratio fell 3068.7% to 0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.21, marking a year-over-year decrease of 3068.7%. This contributed to the annual value of 0.4 for FY2024, which is 21008.51% up from last year.
  • Per Evoke Pharma's latest filing, its Equity Ratio stood at 0.21 for Q3 2025, which was down 3068.7% from 0.27 recorded in Q2 2025.
  • Over the past 5 years, Evoke Pharma's Equity Ratio peaked at 0.5 during Q2 2022, and registered a low of 0.36 during Q4 2023.
  • Its 5-year average for Equity Ratio is 0.25, with a median of 0.31 in 2024.
  • Per our database at Business Quant, Evoke Pharma's Equity Ratio soared by 85171.46% in 2021 and then tumbled by 20588.39% in 2023.
  • Evoke Pharma's Equity Ratio (Quarter) stood at 0.34 in 2021, then grew by 2.5% to 0.34 in 2022, then crashed by 205.88% to 0.36 in 2023, then surged by 210.09% to 0.4 in 2024, then plummeted by 46.52% to 0.21 in 2025.
  • Its Equity Ratio was 0.21 in Q3 2025, compared to 0.27 in Q2 2025 and 0.36 in Q1 2025.